Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 19.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,090 shares of the biopharmaceutical company’s stock after buying an additional 6,320 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.07% of Agios Pharmaceuticals worth $1,737,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Farallon Capital Management LLC boosted its stake in shares of Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the period. Marshall Wace LLP boosted its position in Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Agios Pharmaceuticals by 23.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after buying an additional 388,381 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Agios Pharmaceuticals by 66.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after acquiring an additional 348,808 shares in the last quarter. Finally, Candriam S.C.A. acquired a new position in shares of Agios Pharmaceuticals in the second quarter worth about $13,922,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 1st. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $52.33.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Trading Up 4.2 %

Shares of NASDAQ AGIO opened at $46.70 on Wednesday. Agios Pharmaceuticals, Inc. has a 12-month low of $20.40 and a 12-month high of $53.28. The company has a market cap of $2.66 billion, a price-to-earnings ratio of 4.11, a price-to-earnings-growth ratio of 0.45 and a beta of 0.75. The stock’s 50 day simple moving average is $44.59 and its 200 day simple moving average is $42.43.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.